胆固醇酯转运蛋白抑制剂的研究进展
摘要
流行病学研究证明,低密度脂蛋白(LDL)和高密度脂蛋白(HDL)是调整心血管疾病风险的独立因子,如何升高HDL日益受到人们的重视。研究表明胆固醇酯转运蛋白(CETP)抑制剂具有较强的升高HDL和抗动脉粥样硬化作用,本文对CETP抑制剂的研究进展综述如下。
出处
《国际心血管病杂志》
2007年第3期177-179,共3页
International Journal of Cardiovascular Disease
参考文献10
-
1[1]Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebocontrolled trial[J].Lancet,2002,360(9326):7-22.
-
2[2]de Grooth GJ,Klerkx AH,Stroes ES.et al.A review of CETP and its relation to atherosclerosis[J].J Lipid Res,2004,45(11):1967-1974.
-
3[3]Cilingiroglu M,Ballantyne C.Endothelial lipase and cholesterol metabolism[J].Curr Atheroscler Rep,2004,6(2):126-130.
-
4[4]Lloyd DB,Lira ME,Wood LS,et al.Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib[J].J Biol Chem,2005,280(15):14918-14922.
-
5[5]Davidson MH,Maki K,Umporowicz D,et al.The safety and immunogenicity of a CETP vaccine in healthy adults[J].Atherosclerosis,2003,169(1):113-120.
-
6[6]Brousseau ME,Schaefer EJ,Wolfe ML,et al.Effeets of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol[J].N Engl J Med,2004,350(15):1505-1515.
-
7[7]Okamoto H,lwamoto Y,Maki M,et al.Effect of JTT-705on cholesteryl ester transfer protein and plasma lipid levels in normolipidemie animals[J].Eur J Pharmacol,2003,466 (1-2):147-154.
-
8[8]Zhang B,Fan P,Shimoji E,et al.Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits[J].Arterioscler Thromb Vasc Biol,2004,24(10):1910-1915.
-
9[9]de Grooth GJ,Kuivenhoven JA,Stalenhoef AF,et al.Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor,JTT-705,in humans:a randomized phaseⅡdoseresponse study[J].Circulation,2002,105(18):2159-2165.
-
10[10]Kuivenhoven JA,de Grooth GJ,Kawamura H,et al.Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in typeⅡdyslipidemia[J].Am J Cardiol,2005,95(9):1085-1088.
-
1郝大洁,李静宏.通心络胶囊治疗冠心病心绞痛的疗效及对血脂的影响[J].中西医结合心脑血管病杂志,2014,12(4):408-409. 被引量：19
-
2曾昌水.通心络胶囊治疗冠心病患者对血脂及对心肌缺血疗效的临床观察[J].安徽医学,2010,31(6):655-657. 被引量：7
-
3周津,郭绪昆,丛洪良.胆固醇酯转运蛋白抑制剂现状及研究进展[J].中国城乡企业卫生,2014,29(4):5-6. 被引量：1
-
4李海燕,张良峰,王新.阿托伐他汀对不同ApoE基因型冠心病患者血脂调控影响的临床研究[J].检验医学,2016,31(B09):314-315. 被引量：1
-
5李景扬.荷丹片治疗高脂血症39例的疗效及安全性评价[J].中西医结合心脑血管病杂志,2012,10(1):109-110. 被引量：10
-
6Patrick Duriez,孙燕（译）.胆固醇酯转运蛋白抑制剂[J].世界临床医学,2008,2(3):460-461.
-
7廖敏蕾,李晓蕙,国为民,薛雅琴.老年高血压动态脉压与左室肥厚及颈动脉斑块的临床研究[J].中国老年学杂志,2006,26(3):397-398. 被引量：1
-
8杨瑞霞,蒋理,宋为娟.健康体检者血尿酸水平与血压相关性研究[J].中国基层医药,2014,21(11):1621-1623. 被引量：1
-
9宋树伟,田晓岚.高血压患者宽脉压对心肌的影响[J].丹东医药,2004(4):12-12.
-
10王国娟,李迎霞,吕芳,吴德云,阿基凤,马维青,王佑民.2型糖尿病患者一级亲属脂联素测定及其意义[J].中国糖尿病杂志,2007,15(10):591-592.
